文献速递贫血与红细胞疾病白血病MDS 与骨髓增殖性肿瘤

FcγRIIIB缺陷在血液与免疫系统疾病患者中的分布

Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
PubMed 文献 · Br J Haematol · 2021-09-20

该研究统计了FcγRIIIB缺陷在普通人群及血液/免疫系统疾病患者中的频率。

核心结论

  • FcγRIIIB缺陷在血液病患者中较免疫系统疾病患者更常见。
  • 血液病患者中该缺陷可能与向AML进展的不良预后相关,需多中心研究证实。

研究设计与样本

  • 回顾性分析患者队列中FcγRIIIB缺陷的频率。
  • 免疫系统疾病患者1815例,血液病患者2147例。

临床怎么用

  • 对血液病患者可关注FcγRIIIB缺陷检测,尤其原发性免疫性血小板减少症、治疗相关髓系肿瘤及伴原始细胞增多的MDS。
  • FcγRIIIB缺陷或可提示AML进展风险,需结合多中心研究进一步验证。

局限性

  • FcγRIIIB缺陷作为AML进展预后因素的结论尚需大型多中心研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB) deficiency is present in ˜0·05% of the general population. Among our patients, FcγRIIIB deficiency was less frequent in those with immune-system disorders (one of 1815 patients, 0·05%) than in those with blood disorders (nine of 2147 patients, 0·42%, P = 0·023): mainly primary immune thrombocytopenia (4·34%), therapy related myeloid neoplasms (1·16%) and myelodysplastic syndrome with excess blasts (1·28%). Four of the nine (44·4%) patients with blood disorders were diagnosed with or quickly evolved to acute myeloid leukaemia (AML), suggesting that FcγRIIIB deficiency could be an adverse prognostic factor for progression to AML that should be confirmed in large multicentre studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Minguela A, Salido EJ, Soto-Ramírez MF, et al. Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. Br J Haematol. 2021. PMID: 34544201. doi:10.1111/bjh.17828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。